Evaluating a new treatment for recurrent gliomas using a specific vaccine and medication.
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma
This study is looking at a new treatment that combines a targeted medication called vorasidenib with a vaccine for patients who have recurring gliomas with a specific genetic mutation, and it aims to see how well this treatment works using special imaging techniques to help improve your health and quality of life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10914132 on NIH RePORTER |
What this research studies
This research investigates a combination therapy using vorasidenib, a targeted medication, and the PEP-IDH1M vaccine for patients with recurrent gliomas that have a specific genetic mutation. The study aims to monitor the effectiveness of this treatment through non-invasive imaging techniques, specifically magnetic resonance spectroscopy. By targeting the mutation that drives tumor growth, the research seeks to improve patient outcomes and quality of life. Patients will be closely monitored for changes in tumor behavior and response to therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with recurrent gliomas harboring the IDH1 mutation.
Not a fit: Patients without the IDH1 mutation or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for patients with recurrent mutant IDH1 gliomas, potentially improving survival and quality of life.
How similar studies have performed: Previous research has shown promising results with similar targeted therapies and immunotherapies in treating gliomas, indicating potential for success in this approach.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Soher, Brian J — Duke University
- Study coordinator: Soher, Brian J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.